,i #aadth ,,congress #ast ,session ,h4 ,r4 #aicd ,,in ,,the ,,house ,,of ,,representatives ,april #bb1 #bjae ,mrs4 ,mc,morris ,rodgers 7for herself and ,mr4 ,israel7 introduced the following bill2 which was referred to the ,committee on ,energy and ,commerce1 and in addition to the ,committee on ,ways and ,means1 for a period to be subsequently determined by the ,speaker1 in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned ,a ,,bill ,to amend title ,,xviii of the ,social ,security ,act to establish a national ,oncology ,medical ,home ,demonstration ,project under the ,medicare program for the purpose of changing the ,medicare payment for cancer care in order to enhance the quality of care and to improve cost efficiency1 and for other purposes4 #a4 ,short title ,this ,act may be cited as the ,cancer ,care ,payment ,reform ,act of #bjae4 #b4 ,establishing an ,oncology ,medical ,home ,demonstration ,project under the ,medicare program to improve quality of care and cost efficiency ,title ,,xviii of the ,social ,security ,act is amended by inserting after section #ahff;,e 7#db ,u4,s4,c4 #acie;cc-#e7 the following new section3 #ahff;,f4 ,oncology ,medical ,home ,demonstration ,project 7a7 ,establishment of demonstration project ,not later than six months after the date of the enactment of this section1 the ,secretary shall establish an ,oncology ,medical ,home ,demonstration ,project 7in this section referred to as the demonstration project7 to make payments in the amounts specified in subsection 7f7 to each participating oncology practice 7as defined in subsection 7b774 7b7 ,definition of participating oncology practice ,for purposes of this section1 the term participating oncology practice means an oncology practice that-- 7#a7 submits to the ,secretary an application to participate in the demonstration program in accordance with subsection 7c72 7#b7 is selected by the ,secretary1 in accordance with subsection 7d71 to participate in the demonstration program2 and 7#c7 is owned by a physician1 or is owned by or affiliated with a hospital1 that submitted a claim for reimbursement in the prior year for an item or service for which payment may be made under part ,b4 7c7 ,application ,to ,participate ,an application by an oncology practice to participate in the demonstration program shall include an attestation to the ,secretary that the practice-- 7#a7 furnishes physicians' services for which payment may be made under part ,b2 7#b7 coordinates oncology services furnished to an individual by the practice with services that are related to such oncology services and that are furnished to such individual by medical professionals 7including oncology nurses7 inside or outside the practice in order to ensure that each such individual receives coordinated care2 7#c7 meaningfully uses electronic health records2 7#d7 will1 not later than one year after the date on which the practice commences its participation in the demonstration project1 be accredited as an ,oncology ,medical ,home by the ,commission on ,cancer1 the ,national ,committee for ,quality ,assurance1 or such other entity as the ,secretary determines appropriate2 7#e7 will repay all amounts paid by the ,secretary to the practice under subsection 7f77#a77;,a7 in the case that the practice does not1 on a date that is not later than #fj days after the date on which the practice submits an application to the ,secretary under subsection 7b77#a71 submit an application to an entity described in paragraph 7#d7 for accreditation as an ,oncology ,medical ,home in accordance with such paragraph2 7#f7 will1 for each year in which demonstration project is conducted1 report to the ,secretary1 in such form and manner as is specified by the ,secretary1 on-- 7,a7 the performance of the practice with respect to not less than ten of the measures described in subsection 7e71 as selected by the practice2 and 7,b7 the level of satisfaction of individuals who are provided with oncology services by the practice for which payment may be made under part ,b1 as measured by a patient satisfaction survey based on the ,consumer ,assessment of ,healthcare ,providers and ,systems survey or by such similar survey as the ,secretary determines appropriate2 7#g7 agrees not to receive the payments described in subclauses 7,i7 and 7,,ii7 of subsection 7f77#a77;,b77iii7 in the case that the practice does not report to the ,secretary in accordance with paragraph 7#f7 with respect to performance of the practice during the #ab-month period beginning on the date on which the practice submits the application described in this subsection to the ,secretary2 7#h7 will1 for each year of the demonstration project1 meet the minimum performance requirements developed under subsection 7e77#d77;,b7 with respect to each of the measures on which the practice has agreed to report under paragraph 7#f77;,a72 and 7#i7 has the capacity to utilize shared decision-making tools that facilitate the incorporation of the patient needs1 preferences1 and circumstances of an individual into the medical plan of the individual and that maintain provider flexibility to tailor care of the individual based on the full range of test and treatment options available to the individual4 7d7 ,selection of participating practices 7#a7 ,in general ,the ,secretary shall1 not later than six months after the date of the enactment of this section1 select oncology practices that submit applications to the ,secretary in accordance with subsection 7c7 to participate in the demonstration program4 7#b7 ,maximum number of practices ,in selecting an oncology practice to participate in the demonstration program under paragraph 7#a71 the ,secretary shall ensure that the participation of such practice in the demonstration project does not1 on the date on which the practice commences its participation in the demonstration project1 increase the total number of oncologists who participate in the demonstration program to a number that is greater than #a1ejj oncologists4 7#c7 ,diversity of practices ,in selecting oncology practices to participate in the demonstration project under paragraph 7#a71 the ,secretary shall1 to the extent practicable1 include in such selection-- 7,a7 small-1 medium-1 and large-sized practices2 and 7,b7 practices located in different geographic areas4 7#d7 ,no penalty for certain opt-outs by practices ,in the case that the ,secretary selects an oncology practice to participate in the demonstration project under paragraph 7#a7 that has agreed to participate in another model1 under section #aaae;,a or otherwise1 for payment under this title for oncology services1 such practice may not be assessed a penalty for electing not to participate in such other payment model if such practice makes such election-- 7,a7 prior to the receipt by the practice of any payment under such model2 and 7,b7 in order to participate in such demonstration project4 7e7 ,measures 7#a7 ,development ,the ,secretary shall use measures described in paragraph 7#b71 and may use measures developed under paragraph 7#c71 to assess the performance of each participating oncology practice1 as compared to other participating oncology practices4 7#b7 ,measures described ,the measures described in this paragraph1 with respect to individuals who receive treatment for cancer from a participating oncology practice1 are the following3 7,a7 ,patient care measures 7i7 ,the percentage of such individuals that receives documented clinical or pathologic staging prior to initiation of a first course of cancer treatment4 7ii7 ,the percentage of such individuals that is undergoing advanced imaging and has been diagnosed with stage ,i or ,,ii breast cancer4 7iii7 ,the percentage of such individuals that is undergoing advanced imaging and has been diagnosed with stage ,i or ,,ii prostate cancer4 7iv7 ,the percentage of such individuals that1 prior to receiving cancer treatment1 had its performance status assessed by the practice4 7v7 ,the percentage of such individuals that-- 7,i7 is undergoing treatment with a chemotherapy regimen provided by the practice2 7,,ii7 has at least a #bj-percent risk of developing febrile neutropenia due to a combination of regimen risk and patient risk factors2 and 7,,iii7 has received from the practice either ,,gcsf or white cell growth factor4 7vi7 ,with respect to such individuals who receive chemotherapy treatment from the practice1 the percentage of such individuals so treated that receives a treatment plan prior to the administration of such chemotherapy4 7vii7 ,with respect to chemotherapy treatments administered to such individuals by the practice1 the percentage of such treatments that adhere to guidelines published by the ,national ,comprehensive ,cancer ,network or such other entity as the ,secretary determines appropriate4 7viii7 ,with respect to antiemetic drugs dispensed by the practice to individuals as part of moderately or highly emetogenic chemotherapy regimens for such individuals1 the extent to which such drugs are administered in accordance with evidence-based guidelines or pathways that are compliant with guidelines published by the ,national ,comprehensive ,cancer ,network or such other entity as the ,secretary determines appropriate4 7,b7 ,resource utilization measures 7i7 ,with respect to emergency room visits in a year by such individuals who are receiving active chemotherapy treatment administered by the practice as of the date of such visits1 the percentage of such visits that is associated with qualified cancer diagnoses of the individuals4 7ii7 ,with respect to hospital admissions in a year by such individuals who are receiving active chemotherapy treatment administered by the practice as of the date of such visits1 the percentage of such admissions that is associated with qualified cancer diagnoses of the individuals4 7,c7 ,survivorship measures 7i7 ,survival rates for such individuals who have been diagnosed with stage ,i through ,,iv breast cancer4 7ii7 ,survival rates for such individuals who have been diagnosed with stage ,i through ,,iv colorectal cancer4 7iii7 ,survival rates for such individuals who have been diagnosed with stage ,i through ,,iv lung cancer4 7iv7 ,with respect to such individuals who receive chemotherapy treatment from the practice1 the percentage of such individuals so treated that receives a survivorship plan not later than #de days after the completion of the administration of such chemotherapy to such individuals4 7v7 ,with respect to such individuals who receive chemotherapy treatment from the practice1 the percentage of such individuals that receives psychological screening4 7,d7 ,end-of-life care measures 7i7 ,the number of times that such an individual receives chemotherapy treatment from the practice not later than #cj days prior to the death of the individual4 7ii7 ,with respect to such individuals who have a stage ,,iv disease and have received treatment for such disease from the practice1 the percentage of such individuals so treated who have had a documented end-of-life care conversation with a physician in the practice or another health care provider who is a member of the cancer care team of the practice4 7iii7 ,with respect to such an individual who is referred to hospice care by a physician in the practice or a health care provider who is a member of the cancer care team of the practice1 regardless of the setting in which such care is provided1 the average number of days that the individual receives hospice care prior to the death of the individual4 7iv7 ,with respect to such individuals who die while receiving care from the practice1 the percentage of such deceased individuals whose death occurred in an acute care setting4 7#c7 ,modification or addition of measures 7,a7 ,in general ,the ,secretary may1 in conjunction with appropriate stakeholders1 modify or add to the measures described in paragraph 7#b74 7,b7 ,appropriate stakeholders described ,for purposes of subparagraph 7,a71 the term appropriate stakeholders includes oncology societies1 oncologists who provide oncology services to one or more individuals for which payment may be made under part ,b1 allied health professionals1 health insurance issuers that have implemented alternative payment models for oncologists1 patients and organizations that represent patients1 and biopharmaceutical and other medical technology manufacturers4 7#d7 ,assessment 7,a7 ,in general ,the ,secretary shall1 for each year in which the demonstration project is conducted1 assess-- 7i7 the performance of each participating oncology practice for such year with respect to the measures on which the practice has agreed to report to the ,secretary under subsection 7c77#f77;,a71 as compared to the performance of other participating oncology practices with respect to such measures2 and 7ii7 the extent to which the practice has1 during such year1 used breakthrough or other best-in-class therapies4 7,b7 ,minimum performance requirements ,the ,secretary shall1 in conjunction with the appropriate stakeholders described in paragraph 7#c77;,b71 develop minimum performance requirements with respect to-- 7i7 each of the measures developed under this subsection2 and 7ii7 the level of satisfaction on which practices agree to report to the ,secretary under subsection 7c77#f77;,b74 7f7 ,payments for participating oncologists 7#a7 ,care coordination management fee 7,a7 ,in general ,subject to subparagraphs 7,d7 and 7,e71 the ,secretary shall1 in addition to any other payments made by the ,secretary under this title to a participating oncology practice1 make payment of a care coordination management fee to each such practice4 7,b7 ,timing of payments ,the care coordination management fee described in subparagraph 7,a7 shall be paid to a participating oncology practice at the end of each of the following periods3 7i7 ,the period that ends #f months after the date on which the practice submits the application described in subsection 7c7 to the ,secretary under subsection 7b77#a74 7ii7 ,the period that ends #ab months after the date on which the practice submits such application to the ,secretary4 7iii7 ,subject to subsection 7c77#g7-- 7,i7 the period that ends #ah months after the date on which the practice submits such application to the ,secretary2 and 7,,ii7 the period that ends #bd months after the date on which the practice submits such application to the ,secretary4 7,c7 ,amount of payment ,the amount of the care coordination management fee described in subparagraph 7,a7 shall be determined by the ,secretary in conjunction with oncologists who provide oncology services for which payment may be made under part ,b4 7#b7 ,payment in subsequent years 7,a7 ,in general ,subject to subparagraphs 7,c7 and 7,d71 the ,secretary shall make payments of an ongoing management fee to each participating oncology practice4 7,b7 ,timing of payments ,the ongoing management fee described in subparagraph 7,a7 shall be paid to a participating oncology practice at the end of the third1 fourth1 and fifth years of the demonstration project4 7,c7 ,aggregate amount of payments ,with respect to each of the dates of payment described in subparagraph 7,b71 the aggregate amount of payments to participating oncology practices on such date shall be determined by-- 7i7 determining the amount by which the aggregate expenditures that would have been expended for the previous year under this title if the demonstration project had not been implemented exceeds the aggregate expenditures under this title for such previous year2 7ii7 calculating the amount that is half of the amount determined under clause 7i72 and 7iii7 subtracting from the amount calculated under clause 7ii7 the total amount of payments made under paragraph 7#a7 that have not1 in a prior application of this clause1 previously been so subtracted from a payment determination made under this subparagraph4 7,d7 ,amount of payments to individual practices 7i7 ,minimum performance requirements ,the ,secretary may not make payments to a practice under subparagraph 7,a7 at the end of a year of the demonstration project described in subparagraph 7,b7 unless the practice meets or exceeds the minimum performance requirements developed under subsection 7e77#d77;,b7 for such year with respect to-- 7,i7 the measures on which the practice has agreed to report to the ,secretary under subsection 7c77#f77;,a72 and 7,,ii7 the level of satisfaction on which the practice has agreed to report to the ,secretary under subsection 7c77#f77;,b74 7ii7 ,consideration of performance assessment ,the ,secretary shall1 in conjunction with the appropriate stakeholders described in subsection 7e77#c77;,b71 determine the amount of a payment to an individual oncology practice under subparagraph 7,a7 for a year4 ,in making a determination under the preceding sentence1 the ,secretary shall take into account the performance assessment of the practice under subsection 7e77#d77;,a7 for the previous year1 as compared to the performance assessment of other participating oncology practices under such subsection for such previous year4 7#c7 ,issuance of guidance ,not later than the date that is six months after the date of the enactment of this section1 the ,secretary shall issue guidance detailing the methodology that the ,secretary will use to implement subparagraphs 7,c7 and 7,d7 of paragraph 7#b74 7g7 ,secretary reports to participating oncology practices ,the ,secretary shall inform each participating oncology practice1 on a quarterly basis1 of-- 7#a7 the performance of the practice during the prior quarter with respect to the measures on which the practice has agreed to report to the ,secretary under subsection 7c77#f77;,a72 and 7#b7 the amount by which the expenditures that would have been expended for the prior quarter under this title by a typical oncology practice if the demonstration project had not been implemented exceeds the actual expenditures by the participating oncology practice under this title for such quarter4 7h7 ,applications ,from ,entities ,to ,provide ,accreditations ,not later than the date that is six months after the date of the enactment of this section1 the ,secretary shall establish a process for the acceptance and consideration of applications from entities for purposes of determining which entities may provide accreditation to practices under subsection 7c77#d7 in addition to the entities described in such subsection4 7i7 ,,gao report ,not later than ,june #a1 #bjai1 the ,comptroller ,general of the ,united ,states shall submit a report to ,congress evaluating the success of the demonstration project that includes an assessment of the impact of the project upon the quality and cost-efficiency of oncology services furnished to individuals under this title1 including an assessment of the satisfaction of such individuals with respect to such services that were furnished under such project4 ,such report shall include recommendations regarding the possible expansion of the demonstration project1 as well as any possible reforms that are based on the demonstration project that can be made to the program under this title with respect to payment for cancer care4 4